Vaccine-induced Immunity in Immunocompromised Patients

NCT06612515 · tracked via the Priya Life Science Germany tracker

Sponsor

University of Cologne

Phase

Observational

Started

2025-03-25

Last updated

2026-05-12

Condition(s) studied

Immunodeficiency

Study summary

Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals.

In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Signed informed consent form * Patients with immunosuppression either by treatment or underlying diseases * Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations * Age of 18 years or older Exclusion Criteria: * Patients unwilling/ineligible for vaccination under current recommendations

Primary outcome measure(s)

Humoral immune response after vaccination — 12 months
To compare antibody titres between different subgroups of immunocompromised patients after vaccination against respiratory virus infections

Trial sites (1)

Facility	City	Region	Status
University Hospital Cologne	Cologne	North Rhine-Westphalia	Recruiting

More University of Cologne trials in Germany

Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy Recruiting

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse Active, not recruiting

Artificial Intelligence(AI) in the Emergency Department (ED) in Cologne Active, not recruiting

Leptospirosis Registry - LeptoScope Recruiting

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06612515 on ClinicalTrials.gov ↗ ← All trials in Germany